Literature DB >> 17984453

Vascular factors predict rate of progression in Alzheimer disease.

M M Mielke1, P B Rosenberg, J Tschanz, L Cook, C Corcoran, K M Hayden, M Norton, P V Rabins, R C Green, K A Welsh-Bohmer, J C S Breitner, R Munger, C G Lyketsos.   

Abstract

BACKGROUND: While there is considerable epidemiologic evidence that cardiovascular risk factors increase risk of incident Alzheimer disease (AD), few studies have examined their effect on progression after an established AD diagnosis.
OBJECTIVE: To examine the effect of vascular factors, and potential age modification, on rate of progression in a longitudinal study of incident dementia.
METHODS: A total of 135 individuals with incident AD, identified in a population-based sample of elderly persons in Cache County, UT, were followed with in-home visits for a mean of 3.0 years (range: 0.8 to 9.5) and 2.1 follow-up visits (range: 1 to 5). The Clinical Dementia Rating (CDR) Scale and Mini-Mental State Examination (MMSE) were administered at each visit. Baseline vascular factors were determined by interview and physical examination. Generalized least-squares random-effects regression was performed with CDR Sum of Boxes (CDR-Sum) or MMSE as the outcome, and vascular index or individual vascular factors as independent variables.
RESULTS: Atrial fibrillation, systolic hypertension, and angina were associated with more rapid decline on both the CDR-Sum and MMSE, while history of coronary artery bypass graft surgery, diabetes, and antihypertensive medications were associated with a slower rate of decline. There was an age interaction such that systolic hypertension, angina, and myocardial infarction were associated with greater decline with increasing baseline age.
CONCLUSION: Atrial fibrillation, hypertension, and angina were associated with a greater rate of decline and may represent modifiable risk factors for secondary prevention in Alzheimer disease. The attenuated decline for diabetes and coronary artery bypass graft surgery may be due to selective survival. Some of these effects appear to vary with age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984453     DOI: 10.1212/01.wnl.0000279520.59792.fe

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  95 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Cerebrovascular disease, β-amyloid, and cognition in aging.

Authors:  Natalie L Marchant; Bruce R Reed; Charles S DeCarli; Cindee M Madison; Michael W Weiner; Helena C Chui; William J Jagust
Journal:  Neurobiol Aging       Date:  2011-11-01       Impact factor: 4.673

3.  Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study.

Authors:  Matthew E Peters; Paul B Rosenberg; Martin Steinberg; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; Kathleen M Hayden; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-05       Impact factor: 4.105

4.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

5.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

6.  Smoking cessation and Alzheimer's disease: facts, fallacies and promise.

Authors:  Janine K Cataldo; Stanton A Glantz
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

7.  Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study.

Authors:  Diana E Clarke; Jean Y Ko; Constantine Lyketsos; George W Rebok; William W Eaton
Journal:  Int Psychogeriatr       Date:  2010-05-18       Impact factor: 3.878

8.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 9.  Vascular risk factors and dementia: how to move forward?

Authors:  Anand Viswanathan; Walter A Rocca; Christophe Tzourio
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 10.  Atrial fibrillation, cognition and dementia: A review.

Authors:  Summer Aldrugh; Mayank Sardana; Nils Henninger; Jane S Saczynski; David D McManus
Journal:  J Cardiovasc Electrophysiol       Date:  2017-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.